KPI data tables
MetLife operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Adjusted ROE |
|---|---|
| Q3 2026 | 19.2 |
| Q2 2026 | 17 |
| Q1 2026 | 17 |
| Q4 2025 | 17.6 |
| Q3 2025 | 16.9 |
| Q2 2025 | 14.6 |
| Q1 2025 | 14.4 |
| Q4 2024 | 15.4 |
| Q3 2024 | 14.6 |
| Q2 2024 | 17.3 |
| Q1 2024 | 13.8 |
| Q4 2023 | 13.8 |
| Q3 2023 | 14.9 |
| Q2 2023 | 14.6 |
| Q1 2023 | 11.3 |
| Q4 2022 | 12.1 |
| Q3 2022 | 10.6 |
| Q2 2022 | 16.4 |
| Q1 2022 | 15.7 |
| Q4 2021 | 15.3 |
| Q3 2021 | 17 |
| Q2 2021 | 17.5 |
| Q1 2021 | 16.5 |
| Q4 2020 | 15.2 |
Source: MetLife Form 8-K Exhibit 99.2 Quarterly Financial Supplement, Corporate Overview adjusted ROE (QTD annualized), five period-end columns oldest to newest. Later filing wins, including the Q1 2023 LDTI restatement of 2022. Earliest window filed 2020-02-05 (https://www.sec.gov/Archives/edgar/data/1099219/000109921920000050/ex992qfsq419doc.htm). Latest window filed 2026-11-04 (https://www.sec.gov/Archives/edgar/data/1099219/000109921926000058/ex992qfs8kdoc.htm).
| Period | Asia GA AUM (amortized cost) |
|---|---|
| Q3 2026 | 144,969 |
| Q2 2026 | 141,211 |
| Q1 2026 | 140,660 |
| Q4 2025 | 140,168 |
| Q3 2025 | 140,892 |
| Q2 2025 | 139,158 |
| Q1 2025 | 134,352 |
| Q4 2024 | 129,959 |
| Q3 2024 | 135,107 |
| Q2 2024 | 126,997 |
| Q1 2024 | 128,618 |
| Q4 2023 | 130,093 |
| Q3 2023 | 124,684 |
| Q2 2023 | 125,266 |
| Q1 2023 | 127,120 |
| Q4 2022 | 126,335 |
| Q3 2022 | 119,302 |
| Q2 2022 | 122,257 |
| Q1 2022 | 129,935 |
| Q4 2021 | 130,310 |
| Q3 2021 | 130,777 |
| Q2 2021 | 129,411 |
| Q1 2021 | 127,695 |
| Q4 2020 | 129,661 |
Source: MetLife Form 8-K Exhibit 99.2 Quarterly Financial Supplement, Asia GA AUM at amortized cost (usd_millions), five period-end columns oldest to newest. Later filing wins. Earliest window filed 2020-05-06 (https://www.sec.gov/Archives/edgar/data/1099219/000109921920000200/ex992qfsq120doc.htm). Latest window filed 2026-11-04 (https://www.sec.gov/Archives/edgar/data/1099219/000109921926000058/ex992qfs8kdoc.htm).
| Period | Japan Life | Japan Accident & Health | Japan Annuities | Japan Other | Other Asia |
|---|---|---|---|---|---|
| Q3 2026 | 122 | 104 | 210 | 2 | 290 |
| Q2 2026 | 152 | 118 | 186 | 2 | 350 |
| Q1 2026 | 164 | 114 | 127 | 1 | 365 |
| Q4 2025 | 168 | 57 | 119 | 1 | 254 |
| Q3 2025 | 212 | 61 | 178 | 1 | 326 |
| Q2 2025 | 155 | 62 | 227 | 2 | 232 |
Source: MetLife Q3 2026 Quarterly Financial Supplement, filed 2026-11-04, Asia Sales on a Constant Currency Basis table (Exhibit 99.2): https://www.sec.gov/Archives/edgar/data/1099219/000109921926000058/ex992qfs8kdoc.htm. Q2 2025 row from the Q2 2026 supplement (https://www.sec.gov/Archives/edgar/data/1099219/000109921926000048/ex992qfs8kdoc.htm). Sales definition: same supplement, Non-GAAP and Other Financial Disclosures. Q3 2026 Exhibit 99.1 (sales $728 million, down 6 percent constant currency): https://www.sec.gov/Archives/edgar/data/1099219/000109921926000058/ex991earningsreleasetables.htm.
| Period | Group Life | Group Non-Medical Health |
|---|---|---|
| Q3 2026 | 2,361 | 2,982 |
| Q2 2026 | 2,367 | 2,957 |
| Q1 2026 | 2,379 | 3,019 |
| Q4 2025 | 2,321 | 2,866 |
| Q3 2025 | 2,328 | 2,814 |
| Q2 2025 | 2,371 | 2,876 |
| Q1 2025 | 2,352 | 2,850 |
Source: MetLife Quarterly Financial Supplement, Group Benefits Other Information table. Q3 2026 Exhibit 99.2, filed 2026-11-04: https://www.sec.gov/Archives/edgar/data/1099219/000109921926000058/ex992qfs8kdoc.htm. Q2 2026 Exhibit 99.2: https://www.sec.gov/Archives/edgar/data/1099219/000109921926000048/ex992qfs8kdoc.htm. Q1 2026 Exhibit 99.2 (Q1 2025 print): https://www.sec.gov/Archives/edgar/data/1099219/000109921926000032/ex992qfsq126.htm. Segment PFO total in Q3 2026 Exhibit 99.1: https://www.sec.gov/Archives/edgar/data/1099219/000109921926000058/ex991earningsreleasetables.htm.
| Period | Group Benefits | Retirement and Income Solutions | Asia | Latin America | EMEA | MetLife Investment Management | Corporate & Other |
|---|---|---|---|---|---|---|---|
| FY 2025 | 25,469 | 12,262 | 6,768 | 6,606 | 2,901 | 932 | 2,470 |
| FY 2024 | 24,870 | 8,594 | 6,757 | 5,936 | 2,548 | 718 | 2,956 |
| FY 2023 | 23,929 | 8,832 | 6,969 | 5,727 | 2,346 | 719 | 3,444 |
Source: MetLife Form 10-K for the year ended 31 December 2025, MD&A adjusted premiums, fees and other revenues by segment (FY 2025 $25,469 / $12,262 / $6,768 / $6,606 / $2,901 / $932 / $2,470 million = $57,408 million consolidated; FY 2024 and FY 2023 on the same table). https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/met-20251231.htm
| Period | Total AUM |
|---|---|
| Q3 2026 | 723.441 |
| Q2 2026 | 748.126 |
| Q1 2026 | 736.291 |
| Q4 2025 | 741.674 |
| Q3 2025 | 632.594 |
| Q2 2025 | 624.287 |
| Q1 2025 | 603.164 |
| Q4 2024 | 585.729 |
Source: MetLife Form 8-K Exhibit 99.2 Quarterly Financial Supplement, Total AUM row in millions converted to usd_billions, five period-end columns oldest to newest. Later filing wins. Q4 2025: https://www.sec.gov/Archives/edgar/data/1099219/000109921926000008/ex992qfsq425.htm. Q1 2026: https://www.sec.gov/Archives/edgar/data/1099219/000109921926000032/ex992qfsq126.htm. Q2 2026: https://www.sec.gov/Archives/edgar/data/1099219/000109921926000048/ex992qfs8kdoc.htm. Q3 2026 (filed 2026-11-04): https://www.sec.gov/Archives/edgar/data/1099219/000109921926000058/ex992qfs8kdoc.htm.